Frank Solomon

Title: Frank Solomon: Innovator in Alzheimer's Research

Introduction

Frank Solomon is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biomedical research, particularly in the study of Alzheimer's disease. With a total of 2 patents, Solomon's work focuses on amyloid precursor-like proteins and their implications in neurodegenerative conditions.

Latest Patents

Solomon's latest patents include innovations related to amyloid precursor-like proteins (APLPs). The first patent, titled "Amyloid precursor-like protein and uses thereof," is directed to isolated APLPs, nucleotide sequences coding for these proteins, and antibodies that can detect APLPs in biological specimens. This invention also encompasses isolated genomic DNA, cDNA, anti-sense RNA, and RNA containing the protein sequence. APLP1 and APLP2 are identified as candidate genes for late-onset familial Alzheimer's disease. The second patent, "Nucleic acid encoding amyloid precursor-like protein and uses thereof," shares similar themes, focusing on the detection and regulation of APLPs in various biological samples.

Career Highlights

Throughout his career, Frank Solomon has worked with prestigious institutions, including The General Hospital Corporation and the Massachusetts Institute of Technology. His research has significantly advanced the understanding of Alzheimer's disease and the role of APLPs in its pathology.

Collaborations

Some of his notable coworkers include Wilma Wasco and Keith Bupp, who have contributed to his research endeavors.

Conclusion

Frank Solomon's innovative work in the field of Alzheimer's research highlights the importance of amyloid precursor-like proteins in understanding and potentially treating this devastating disease. His contributions continue to influence the scientific community and pave the way for future advancements in neurodegenerative research.